Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)

Inclusion Criteria: Provide signed and dated informed consent form. * Aged 18 years or older. * Have histologic evidence of malignant neoplasm that may have been obtained from the primary tumor or metastatic lymph node. * Have a clinical decision made to receive external beam radiation therapy (EBRT) with curative intent, with or without concomitant chemotherapy. * Have a good performance status (ECOG score 0-2) evaluated during screening (4 weeks prior to baseline imaging). * Be willing to comply with all study procedures. * Be willing to participate for the duration of the study. * Have elevated dosimetric risk mainly characterized by any of the following criteria: * D30\>50Gy: 30% of the whole-mandible volume received a dose greater than 50 Gy * V44 ≥ 42%: at least 42% of the volume received a dose of 44 Gy or more or * V58 ≥ 25%: at least 25% of the volume received a dose of 58 Gy or more. Exclusion Criteria: Unable to tolerate DW-MRI or DCE-MRI; * Having an estimated GFR \< 30 ml/min/1.73 m2; * Contraindication to MRI (e.g., non-MRI compatible metallic implants) * Pregnant females * Unable or unwilling to give written, informed consent to undergo MRI imaging. * Claustrophobia * Unable to obtain imaging studies of adequate quality to assess imaging-based biomarkers.